196 related articles for article (PubMed ID: 23588390)
1. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
2. UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Neutsch L; Wambacher M; Wirth EM; Spijker S; Kählig H; Wirth M; Gabor F
Int J Pharm; 2013 Jun; 450(1-2):163-76. PubMed ID: 23628404
[TBL] [Abstract][Full Text] [Related]
3. LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.
Anzengruber M; Wimmer L; Szuchar R; Skoll K; Wirth M; Gabor F
Eur J Pharm Sci; 2023 Jan; 180():106330. PubMed ID: 36379358
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
5. Poly - (l) - glutamic acid drug delivery system for the intravesical therapy of bladder cancer using WGA as targeting moiety.
Apfelthaler C; Anzengruber M; Gabor F; Wirth M
Eur J Pharm Biopharm; 2017 Jun; 115():131-139. PubMed ID: 28237713
[TBL] [Abstract][Full Text] [Related]
6. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
7. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y
Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
Joshi G; Kumar A; Sawant K
Eur J Pharm Sci; 2014 Aug; 60():80-9. PubMed ID: 24810394
[TBL] [Abstract][Full Text] [Related]
9. Lectin bioconjugates trigger urothelial cytoinvasion--a glycotargeted approach for improved intravesical drug delivery.
Neutsch L; Eggenreich B; Herwig E; Marchetti-Deschmann M; Allmaier G; Gabor F; Wirth M
Eur J Pharm Biopharm; 2012 Oct; 82(2):367-75. PubMed ID: 22889683
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Jaidev LR; Krishnan UM; Sethuraman S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():40-7. PubMed ID: 25492170
[TBL] [Abstract][Full Text] [Related]
13. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
14. Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers.
Şenyiğit ZA; Karavana SY; İlem-Özdemir D; Çalışkan Ç; Waldner C; Şen S; Bernkop-Schnürch A; Baloğlu E
Int J Nanomedicine; 2015; 10():6493-507. PubMed ID: 26508855
[TBL] [Abstract][Full Text] [Related]
15. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
16. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
17. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Aggarwal S; Yadav S; Gupta S
J Biomed Nanotechnol; 2011 Feb; 7(1):137-8. PubMed ID: 21485840
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
19. Microemulsions for intravesical delivery of gemcitabine.
Tsai YH; Hsieh YH; Huang YB; Chang JS; Huang CT; Wu PC
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1461-5. PubMed ID: 21048337
[TBL] [Abstract][Full Text] [Related]
20. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
